Fresh2 Group Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on Fresh2 Group's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | n/a |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
AnPac Bio announces plan to implement ADS ratio change
Oct 18AnPac Bio-Medical Science announces management changes
Oct 03AnPac Bio-Medical Science signed equity investment totaling $3.67M with new investor Group
Sep 27AnPac Bio appoints Yuyang Cui as co-chief executive officer
Aug 05AnPac Bio stock soars 15% after securing first disease treatment patent in U.S.
Jun 18AnPac Bio wins new US patent for multi-cancer detection
Feb 01AnPac Bio (ANPC) skyrockets 136% on advancement in detecting pre-cancer diseases
Dec 14Industry Analysts Just Upgraded Their AnPac Bio-Medical Science Co., Ltd. (NASDAQ:ANPC) Revenue Forecasts By 55%
Dec 11AnPac Bio-Medical rallies on Q3 record test volume; FY20 revenue estimated at +100%
Nov 25AnPac Bio's Chinese company secures COVID-19 nucleic acid test certification; shares +33%
Nov 02Revenue & Expenses Breakdown
How Fresh2 Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 17 | -136 | 116 | 12 |
31 Mar 23 | 11 | -110 | 92 | 9 |
31 Dec 22 | 12 | -102 | 83 | 10 |
30 Sep 22 | 11 | -61 | 58 | 8 |
30 Jun 22 | 9 | -70 | 58 | 11 |
31 Mar 22 | 18 | -104 | 92 | 15 |
31 Dec 21 | 18 | -119 | 102 | 16 |
30 Sep 21 | 25 | -98 | 99 | 12 |
30 Jun 21 | 26 | -81 | 92 | 10 |
31 Mar 21 | 22 | -88 | 94 | 12 |
31 Dec 20 | 21 | -80 | 94 | 12 |
30 Sep 20 | 12 | -112 | 103 | 14 |
30 Jun 20 | 11 | -122 | 107 | 13 |
31 Mar 20 | 10 | -105 | 91 | 11 |
31 Dec 19 | 11 | -101 | 83 | 10 |
30 Sep 19 | 12 | -69 | 64 | 9 |
31 Dec 18 | 10 | -42 | 38 | 10 |
31 Dec 17 | 6 | -39 | 31 | 11 |
Quality Earnings: Insufficient data to determine if FREH.Y has high quality earnings.
Growing Profit Margin: Insufficient data to determine if FREH.Y's profit margins have improved over the past year.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if FREH.Y's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Insufficient data to compare FREH.Y's past year earnings growth to its 5-year average.
Earnings vs Industry: Insufficient data to determine if FREH.Y's earnings growth over the past year exceeded the Biotechs industry average.
Return on Equity
High ROE: FREH.Y has a negative Return on Equity (0%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2025/03/17 01:45 |
End of Day Share Price | 2025/03/14 00:00 |
Earnings | 2023/06/30 |
Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Fresh2 Group Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Theodore O'Neill | Litchfield Hills Research, LLC |